Sep 24, 2020NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12- Novel Peptide to Advance to Phase 2 for the Treatment of Severe Burns -
Oct 31, 2017NeoMatrix Therapeutics Enters Clinical Stage as IND for NMT-cP12 Goes Into Effect- Potential First-in-Class Treatment for Serious Burn Injuries Targets PDGF -